Blood test may spare gastric cancer patients from unnecessary chemo
NCT ID NCT07257380
First seen Dec 02, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This study tests whether a blood test that detects tiny traces of cancer DNA (ctDNA) can guide treatment after gastric cancer surgery. The goal is to see if patients with no detectable cancer DNA can safely skip additional chemotherapy, avoiding harsh side effects. About 90 adults with advanced gastric cancer who received chemo before surgery will participate. The approach aims to personalize care and reduce unnecessary treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.